Talazoparib, another promising PARP-i, has shown, in vitro, a significantly higher selectivity and efficacy (20- to over 200-fold greater) against tumor cells harboring BRCA1/2 or PTEN mutations compared to earlier PARP inhibitors [40]. The gene discussed is PARP1; the disease is neoplasm.